Opportunity #4 - Scope creep demands stronger checks and balances

August 19, 2026 Latest News BioPharma Comment

This is a preview of subscriber content

Subscribe now to continue reading.

Opportunity number four for industry in the pending negotiation of new agreements may be the hardest to achieve, but it also offers the greatest potential to put Australia’s medicines decision-making framework on track. …

Subscribe now to continue reading.

Latest Video

Opportunity #1 - biosimilar policy failure has become impossible to ignore
August 18, 2026 - Latest News
Has any patient ever said they accept a rejection because of the Kaplan-Meier curve?
August 17, 2026 - Latest News
OncoSil secures FDA approval for targeted bile duct cancer device
August 17, 2026 - Latest News
Dimerix takes control of US development pathway for new kidney injury treatment
August 17, 2026 - Australian Biotech
Pharmac aims to pivot toward faster process and broader value framework
August 17, 2026 - Latest News

Opportunity #4 - Scope creep demands stronger checks and balances

This is a preview of subscriber content

Latest Video

Most Read

Opportunity #1 - biosimilar policy failure has become impossible to ignore

Has any patient ever said they accept a rejection because of the Kaplan-Meier curve?

OncoSil secures FDA approval for targeted bile duct cancer device

Dimerix takes control of US development pathway for new kidney injury treatment

Pharmac aims to pivot toward faster process and broader value framework

New Stories

Rare autoimmune diseases impose a $1.2 billion annual burden on Australians

Recce advances pivotal diabetic foot infection trial with active antibiotic comparator arm

New Zealand researchers honoured for work tackling superbugs and blood cancer

Novo Nordisk backs care for rural health professionals in southern NSW

Opportunity #3 - finally deliver on the repeated claims of patient-centricity

Departmental restructure formally splits medicines financing from pharmacy services

Wesfarmers Health evolves its loyalty program with new Pulse Rewards

Sign In

Opportunity #4 - Scope creep demands stronger checks and balances

This is a preview of subscriber content

Latest Video

Most Read

Opportunity #1 - biosimilar policy failure has become impossible to ignore

Has any patient ever said they accept a rejection because of the Kaplan-Meier curve?

OncoSil secures FDA approval for targeted bile duct cancer device

Dimerix takes control of US development pathway for new kidney injury treatment

Pharmac aims to pivot toward faster process and broader value framework

Follow Us

New Stories

Rare autoimmune diseases impose a $1.2 billion annual burden on Australians

Recce advances pivotal diabetic foot infection trial with active antibiotic comparator arm

New Zealand researchers honoured for work tackling superbugs and blood cancer

Novo Nordisk backs care for rural health professionals in southern NSW

Opportunity #3 - finally deliver on the repeated claims of patient-centricity

Departmental restructure formally splits medicines financing from pharmacy services

Wesfarmers Health evolves its loyalty program with new Pulse Rewards